First Patient Dosed in VAXINIA Intravenous Cohort 2
Filed with ASX · · 3 pages · English
part of intravenous (IV) cohort 2 of the trial. This follows the announcement on 11 November 2022 that IV cohort 1 had cleared, paving the way for the commencement of cohort 2. The intratumoral (IT) arm continues to progress after the first patient was dosed in cohort 2 on 27 October 2022. The multicenter Phase 1 MAST trial commenced by delivering a low dose of VAXINIA to patients with metastatic
Story so far
Earlier from Imugene
- Imugene onCARlytics with Estrella ARTEMIS T Cells SITC
- Dose escalates In Phase I Clinical Trial of New Oncolytic Vi
- Imugene onCARlytics with blinatumomab SITC presentation
- Europe Patent granted for iNKT Cell Therapy Platform
- First patient dosed in VAXINIA intratumoral cohort 2
Later from Imugene
- CHECKVacc Data Presented at the 2022 SABC Symposium
- Imugene Receives Vaxinia Ethics Approval in Australia
- Imugene VAXINIA trial advances to Combination Cohort
- Imugene PD1-Vaxx Immunotherapy Patent Granted in the US
- First Patients Dosed in Combination Study of VAXINIA
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene